Attovia Therapeutics has entered the public market with a strategy centered on Attobody, a biparatopic antibody platform designed to turn established immunology targets into next-generation biologics. The stock last traded at $19.86, up 3.6% on the session, giving the company a market capitalization of about $287.9 million, though it has fallen 9.32% from its early $21.90 print over its first eight trading days. Its lead program, ATTO-1310, is described in the S-1 as a “novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31” and is in a Phase 1 trial in healthy volunteers and patients for chronic pruritus and high-itch atopic dermatitis. The company is also targeting chronic pruritus of unknown origin and cholestatic pruritus in primary biliary disease. Behind it are ATTO-2306, a bispecific (engineered to hit two targets) aimed at IL-13 and IL-31 that is in IND-enabling studies, and ATTO-1091, a trispecific (engineered to hit three targets) candidate for inflammatory bowel disease designed to block TL1A, IL-23 and integrin a4ß7. Founded in 2023, Attovia said it had raised $255.8 million as of March 31, 2026, including a $90 million Series C disclosed ahead of the IPO. The prospectus says future revenue depends on whether ATTO-1310, ATTO-2306, ATTO-1091 or later candidates win approval, while development of the Attobody platform, manufacturing partnerships, product liability exposure and trial timing remain key risks. Near-term attention is on Phase 1 data for ATTO-1310 and IND clearance for ATTO-2306 targeted for the first half of 2027.